MedTrace Logo

CDP323 Biomarker Study

NCT00726648 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2011-09-12

No results posted yet for this study

Summary

Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.

Conditions

Interventions

DRUG

CDP323

50mg capsules, 100mg bid for 4 weeks

DRUG

CDP323

250mg capsules, 500mg bid for 4 weeks

DRUG

CDP323

250mg capsules, 1000mg bid for 4 weeks

DRUG

CDP323

250mg capsules, 1000mg daily for 4 weeks

DRUG

Placebo

placebo capsules for 4 weeks

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · UCB Pharma

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00726648 on ClinicalTrials.gov